Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.74 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | CCR3 | P51677 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989203 | 0.92 | SIGMAR1 (0.63) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL159371 | 0.87 | SIGMAR1 (0.61) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL12535945 | 0.86 | SIGMAR1 (0.74) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL576868 | 0.85 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL242970 | 0.85 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL8188324 | 0.85 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL2489199 | 0.85 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1041303 | 0.85 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1415730 | 0.85 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| Water SCHEMBL8695926 | 0.83 | SIGMAR1 (0.95) | SIGMAR1MC4RDRD4LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843569-A | Isoquinoline acrylamide CDK8 inhibitor, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-04-09 | — | — | CN | claimed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | claimed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | claimed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | claimed |
| CN-115667255-A | Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2023-01-31 | — | — | CN | claimed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | claimed |
| CN-109923108-B | Pyridyl-substituted indole compounds | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | claimed |
| US-20210393614-A1 | QUINONE REDUCTASE 2 INHIBITORS FOR USE AS NEUROPROTECTIVE AGENTS | UNIV DUKE (US) | 2021-12-23 | — | — | US | claimed |
| US-5130303-A | Pyridine derivative administering | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-07-14 | — | — | US | claimed |
| WO-1992011232-A1 | CHELATING AGENTS | NYCOMED IMAGING AS (NO) | 1992-07-09 | — | — | WO | claimed |
| EP-0426180-A2 | Imidazo[4,5-b] quinolinyloxyalkanoic acid amides with enhanced water solubility | Bristol-Myers Squibb Company (US) | 1991-05-08 | — | — | EP | claimed |
| US-4943573-A | ENZYME INHIBITORS, CARDIOTONIC, ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-07-24 | — | — | US | claimed |
| EP-0374808-A2 | Xanthin derivatives having an adenosin-antagonist activity | BOEHRINGER INGELHEIM KG (DE) | 1990-06-27 | — | — | EP | claimed |
| EP-0353692-A2 | Drug effect-enhancing agent for antitumor drug | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-02-07 | — | — | EP | claimed |
| US-4886806-A | ANTIINFLAMMATORY AGENTS | KALI-CHEMIE PHARMA GMBH (DE) | 1989-12-12 | — | — | US | claimed |
| EP-0207674-A2 | 1,4-Dihydropyridine derivatives, their preparation and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | claimed |
| EP-0186977-A2 | Renin-inhibitory dipeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1986-07-09 | — | — | EP | claimed |
| EP-0079740-B1 | ANTHRANILOYLOXYALKANOATES | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-11-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | SIGMAR1 2968/4885MC4R 3625/4885DRD4 3477/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | SIGMAR1 4725/4885MC4R 1754/4885DRD4 2590/4885 |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | SIGMAR1 3814/4885MC4R 2468/4885DRD4 4803/4885 |
| US-20210393614-A1 | QUINONE REDUCTASE 2 INHIBITORS FOR USE AS NEUROPROTECTIVE AGENTS | NQO1, TXNRD2, NQO2 | SIGMAR1 3840/4885MC4R 4519/4885DRD4 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.